UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 05, 2025

 

 

Sarepta Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware			001-14895	93-0797222
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
215 First Street
Cambridge, Massachusetts				02142
(Address of Principal Executive Offices)				(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (617) 274-4000

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		SRPT		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 5, 2025, Sarepta Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted to approve Amendment No. 4 (the “2018 Plan Amendment”) to the Company’s 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan Amendment increases the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2018 Plan by 4,300,000 shares to 17,487,596 shares. The foregoing summary of the 2018 Plan Amendment is qualified in its entirety by reference to the full text of the 2018 Plan Amendment, which is attached as Exhibit 10.1 hereto and is incorporated herein by reference.

At the Annual Meeting, the Company’s stockholders also voted to approve Amendment No. 3 (the “2016 ESPP Amendment”) to the Amended and Restated 2013 Employee Stock Purchase Plan, as amended and restated on June 27, 2016 (the “2016 ESPP”). The 2016 ESPP Amendment increases the number of shares of the Company’s common stock authorized for issuance under the 2016 ESPP by 300,000 shares to 1,700,000 shares. The foregoing summary of the 2016 ESPP Amendment is qualified in its entirety by reference to the full text of the 2016 ESPP Amendment, which is attached as Exhibit 10.2 hereto and is incorporated herein by reference.

Item 5.07. Submission of Matters to a Vote of Security Holders.

The following is a brief description of each proposal voted upon at the Annual Meeting and the final voting results for each such proposal. As of the record date for the Annual Meeting, April 8, 2025, there were 98,256,898 shares of common stock outstanding and entitled to vote at the Annual Meeting. There were 84,586,114 shares of common stock entitled to vote at the Annual Meeting present online or represented by proxy, which represented 86.09% of the outstanding shares entitled to vote at the Annual Meeting, and which constituted a quorum for the transaction of business.

Proposal 1: Election of Directors

The director nominees listed below were elected to serve on the Company’s board of directors as members of Class II for a term of two years. The results of the vote were as follows:

 

Name of Nominee		For		Against		Abstain		Broker Non-Votes
Richard J. Barry		64,757,685		9,565,547		60,768		10,202,114
M. Kathleen Behrens, Ph.D.		69,004,024		5,336,943		43,033		10,202,114
Stephen L. Mayo, Ph.D.		73,289,653		1,051,656		42,691		10,202,114
Claude Nicaise, M.D.		71,006,475		3,334,914		42,611		10,202,114

 

Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation

The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers for 2024. The results of the advisory vote were as follows:

 

For		Against		Abstain		Broker Non-Votes
72,144,292		2,176,998		62,710		10,202,114

 

Proposal 3: Amendment to the Company’s 2018 Equity Incentive Plan

The stockholders approved the 2018 Plan Amendment. The results of the vote were as follows:

 

For		Against		Abstain		Broker Non-Votes
71,084,947		3,248,699		50,354		10,202,114

 

Proposal 4: Amendment to the Company’s Amended and Restated 2013 Employee Stock Purchase Plan

The stockholders approved the 2016 ESPP Amendment. The results of the vote were as follows:

 

For		Against		Abstain		Broker Non-Votes
73,725,724		629,170		29,106		10,202,114

 

Proposal 5: Ratification of KPMG as the Company’s Independent Registered Public Accounting Firm

The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the current year ending December 31, 2025. The results of the vote were as follows:

 

For		Against		Abstain
80,588,115		3,875,497		122,502

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit Number	Description
10.1	Amendment No. 4 to the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan
10.2	Amendment No. 3 to the Sarepta Therapeutics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan
104	The cover page from this Current Report on Form 8-K of Sarepta Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit 101

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

			Sarepta Therapeutics, Inc.
Date:	June 6, 2025	By:	/s/ Douglas S. Ingram
			Douglas S. Ingram President and Chief Executive Officer